NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mosanna Therapeutics

Mosanna Therapeutics

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://mosanna.com/

Last Round

Series A

Jun 9, 2025

Total Funding Raised

$80M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Mosanna Therapeutics is a biotechnology company that develops pharmaceutical therapeutics designed to treat obstructive sleep apnea through non-mechanical approaches.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

obstructive sleep apneaOSAbiotechnologyintranasal therapysleep apnea treatmentclinical-stage biotechsmall moleculedrug developmentairway dilatorCPAP alternativepharmaceutical R&Dclinical trialsnasal spraysleep medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mosanna Therapeutics Comparables

Compare Mosanna Therapeutics with similar companies based on industry and business-model similarity.

Mosanna Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Apnimed
89%
Incannex Healthcare Inc.
76%
Shionogi & Co.
68%

Mosanna Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 9, 2025
SeedJul 13, 2022

Key People

Founding team and executive leadership

David Weber

Chief Executive Officer

Executive Team

Mosanna Therapeutics Investors

Notable investors and investment history

Mosanna Therapeutics investors
InvestorRounds
EQT Life SciencesSeries A
ForbionSeries A
Forty51 VenturesSeries A, Seed
Norwest Venture PartnersSeries A
Pivotal bioVenture PartnersSeries A
Pivotal bioVenture PartnersSeries A
Supermoon CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors grew 140% MoM, reaching 2.1K.

  • Jun 20, 2025

    David Weber appointed President and CEO.

Mosanna Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mosanna Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mosanna Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range15
Year Founded2022
Last FundingJun 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.